Inhibikase Therapeutics Inc (IKT)

[conix]

IKT looks interesting down here. RSI is way below 30 (Oversold). 10-Q just filed on Monday--and got weaker.


Company Highlights:

*Multi-therapeutic pipeline with emphasis on neurodegeneration inside and outside of the brain.

*5 clinical programs in neurodegeneration and 1 clinical in oncology by end of '21

*Ongoing Phase 1 Trial with ikT-148009 reaches therapeutic drug exposures seen in animal models at 25 mg oral dose 1x per day in humans

*Over $20 million in grants/contracts from NIH, DoD, Michael J. Fox Foundation and Georgia Research Alliance

* Cash in excess of $50 million

*Highly experienced and recognized BOD and Scientific Advisory board

Market Cap: $52 million
52 Week H-L: $1.74 - 11.80
Current Price: $1.91

Website: http://www.inhibikase.com